Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.